Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

NCT01923857 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hypogonadism

Interventions

DRUG: Androxal 25 mg

Sponsor

Repros Therapeutics Inc.